This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (29)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Pediatrics  • Pediatrics, Other  • World Health  • Randomized Controlled Trial  • Malaria  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Randomized Trial

Grant Dorsey, MD, PhD; Sarah Staedke, MD; Tamara D. Clark, MPH; Denise Njama-Meya, MB ChB, MSc; Bridget Nzarubara, MB ChB; Catherine Maiteki-Sebuguzi, MB ChB; Christian Dokomajilar, BA; Moses R. Kamya, MB ChB, MMed; Philip J. Rosenthal, MD

JAMA. 2007;297(20):2210-2219.

Context  Combination therapy is now widely advocated as first-line treatment for uncomplicated malaria in Africa. However, it is not clear which treatment regimens are optimal or how to best assess comparative efficacies in highly endemic areas.

Objective  To compare the efficacy and safety of 3 leading combination therapies for the treatment of uncomplicated malaria.

Design, Setting, and Participants  Single-blind randomized clinical trial, conducted between November 2004 and June 2006, of treatment for all episodes of uncomplicated malaria in children in an urban community in Kampala, Uganda. A total of 601 healthy children (aged 1-10 years) were randomly selected and were followed up for 13 to 19 months, receiving all medical care at the study clinic.

Interventions  Study participants were randomized to receive 1 of 3 combination therapies (amodiaquine plus sulfadoxine-pyrimethamine, amodiaquine plus artesunate, or artemether-lumefantrine) when diagnosed with their first episode of uncomplicated malaria. The same assigned treatment was given for all subsequent episodes.

Main Outcome Measure  28-Day risk of parasitological failure (unadjusted and adjusted by genotyping to distinguish recrudescence from new infection) for each episode of uncomplicated malaria treated with study drugs.

Results  Of enrolled children, 329 of 601 were diagnosed with at least 1 episode of uncomplicated malaria, and 687 episodes of Plasmodium falciparum malaria were treated with study drugs. The 28-day risk of treatment failure (unadjusted by genotyping) for individual episodes of malaria were 26.1% (95% CI, 21.1%-32.1%) for amodiaquine plus sulfadoxine-pyrimethamine, 17.4% (95% CI, 13.1%-23.1%) for amodiaquine plus artesunate, and 6.7% (95% CI, 3.9%-11.2%) for artemether-lumefantrine (P<.05 for all pairwise comparisons). When only recrudescent treatment failures were considered, the risks of failure were 14.1% (95% CI, 10.3%-19.2%), 4.6% (95% CI, 2.5%-8.3%), and 1.0% (95% CI, 0.3%-4.0%) for the same order of study drugs, respectively (P.008 for all pairwise comparisons, except amodiaquine plus artesunate vs artemether-lumefantrine, P = .05). There were no deaths or cases of severe malaria. Significant reductions in anemia (9.3% [95% CI, 7.0%-12.0%] at enrollment vs 0.6% [95% CI, 0.1%-2.2%] during the last 2 months of follow-up; P<.001) and asymptomatic parasitemia (18.6% [95% CI, 15.5%-22.1%] at enrollment vs 2.3% [95% CI, 1.5%-3.5%] during the last 2 months of follow-up; P<.001) were observed according to routine testing.

Conclusions  Artemether-lumefantrine was the most efficacious treatment for uncomplicated malaria in the study population. With all study regimens, the provision of prompt and reasonably effective facility-based treatment was associated with good outcomes in long-term health measures.

Trial Registration  isrctn.org Identifier: ISRCTN37517549

Author Affiliations: Department of Medicine, San Francisco General Hospital, University of California, San Francisco (Drs Dorsey and Rosenthal, Ms Clark, and Mr Dokomajilar); London School of Hygiene and Tropical Medicine, London, England (Dr Staedke); and Makerere University Medical School, Kampala, Uganda (Drs Njama-Meya, Nzarubara, Maiteki-Sebuguzi, and Kamya).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of Severe Sepsis with Artemether-Lumefantrine Is Associated with Decreased Mortality in Ugandan Patients without Malaria
Moore et al.
Am J Trop Med Hyg 2009;80:723-728.
ABSTRACT | FULL TEXT  

The Inhibitory Effect of 2-Halo Derivatives of D-Glucose on Glycolysis and on the Proliferation of the Human Malaria Parasite Plasmodium falciparum
van Schalkwyk et al.
J. Pharmacol. Exp. Ther. 2008;327:511-517.
ABSTRACT | FULL TEXT  

Artesunate for the Treatment of Severe Falciparum Malaria
Rosenthal
NEJM 2008;358:1829-1836.
FULL TEXT  

Malaria Still Looms Large
JWatch Infect. Diseases 2007;2007:1-1.
FULL TEXT  

Malaria 2007--Progressing Research, Persisting Challenges
Zuccotti and DeAngelis
JAMA 2007;297:2285-2286.
FULL TEXT